Principal Investigator
Mark Leibowitz, MD
Collaborative Neuroscience Network
- 2 trials
- 1 compound
Therapeutic focus
- Major Depressive Disorder
- Schizophrenia
All trials (2)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT03642964 | Phase 2 | Completed | ALTO-207 | Alto Neuroscience, Inc. |
| NCT01955564 | Phase 1 | Completed | — | Newron Pharmaceuticals SPA |
Compounds studied
Trial sites (1)
- Long Beach, California, United States
Investigator and site data mirrored fromClinicalTrials.gov (public domain).